Gastritis and Gastropathy

Textbook of Gastroenterology, Fifth Edition

Volumn 1, Issue , 2009, Pages 1005-1025

  Washington, Mary Kay ^a   Peek Jr , Richard M ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Autoimmune gastritis; Chemical (reactive) gastropathy (NSAID and bile reflux); Chronic gastritis histological features; gastritis and gastropathy classification of gastritis using Sydney system; Gastritis of cardia; Helicobacter pylori induced gastritis; Hemorrhagic gastropathy; Infectious gastritis (excluding H. pylori); Multifocal atrophic gastritis

Indexed keywords

EID: 84875197552     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303254.ch42     Document Type: Chapter

References (237)

1. Peek RM Jr, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nature Rev Cancer 2002; 2: 28.
2. Peek RM Jr, Crabtree JE. Helicobacter infection and gastric neoplasia. J Pathol 2006; 208: 233.
3. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 1: 1311.
4. Marshall BJ, Armstrong JA, McGechie DB, et al. Attempt to fulfil Koch's postulates for pyloric Campylobacter. Med J Aust 1985; 142: 436.
5. Correa P. Helicobacter pylori and gastric cancer: state of the art. Cancer Epidemiol Biomarkers Prev 1996; 5: 477.
6. Peterson WL. Helicobacter pylori and peptic ulcer disease. N Engl J Med 1991; 324: 1043.
7. Karnes WE Jr, Samloff IM, Siurala M, et al. Positive serum antibody and negative tissue staining for Helicobacter pylori in subjects with atrophic body gastritis. Gastroenterology 1991; 101: 167.
8. Forman D, Newell DG, Fullerton F, et al. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. Br Med J 1991; 302: 1302.
9. Nomura A, Stemmermann GN, Chyou PH, et al. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 1991; 325: 1132.
10. Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991; 325: 1127.
11. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, et al. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991; 338: 1175.
12. Wotherspoon AC, Doglioni C, de Boni M, et al. Antibiotic treatment for low-grade gastric MALT lymphoma. Lancet 1994; 343: 1503.
13. Watanabe Y, Kurata JH, Mizuno S, et al. Helicobacter pylori infection and gastric cancer. A nested case-control study in a rural area of Japan. Dig Dis Sci 1997; 42: 1383.
14. Siman JH, Forsgren A, Berglund G, et al. Association between Helicobacter pylori and gastric carcinoma in the city of Malmo, Sweden. A prospective study. Scand J Gastroenterol 1997; 32: 1215.
15. Sipponen P, Kosunen TU, Valle J, et al. Helicobacter pylori infection and chronic gastritis in gastric cancer. J Clin Pathol 1992; 45: 319.
16. Hansson LE, Engstrand L, Nyren O, et al. Helicobacter pylori infection: independent risk indicator of gastric adenocarcinoma. Gastroenterology 1993; 105: 1098.
17. Hu PJ, Mitchell HM, Li YY, et al. Association of Helicobacter pylori with gastric cancer and observations on the detection of this bacterium in gastric cancer cases. Am J Gastroenterol 1994; 89: 1806.
18. Kikuchi S, Wada O, Nakajima T, et al. Serum anti-Helicobacter pylori antibody and gastric carcinoma among young adults. Research Group on Prevention of Gastric Carcinoma among Young Adults. Cancer 1995; 75: 2789.
19. Kokkola A, Valle J, Haapiainen R, et al. Helicobacter pylori infection in young patients with gastric carcinoma. Scand J Gastroenterol 1996; 31: 643.
20. Barreto-Zuniga R, Maruyama M, Kato Y, et al. Significance of Helicobacter pylori infection as a risk factor in gastric cancer: serological and histological studies. J Gastroenterol 1997; 32: 289.
21. Miehlke S, Hackelsberger A, Meining A, et al. Histological diagnosis of Helicobacter pylori gastritis is predictive of a high risk of gastric carcinoma. Int J Cancer 1997; 73: 837.
22. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001; 49: 347.
23. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784.
24. Correa P. Is gastric cancer preventable? Gut 2004; 53: 1217.
25. Blanchard TG, Drakes ML, Czinn SJ. Helicobacter infection: pathogenesis. Curr Opin Gastroenterol 2004; 20: 10.
26. Moss SF, Blaser MJ. Mechanisms of disease: Inflammation and the origins of cancer. Nat Clin Pract Oncol 2005; 2: 90.
27. Ernst PB, Peura DA, Crowe SE. The translation of Helicobacter pylori basic research to patient care. Gastroenterology 2006; 130: 188.
28. Beswick EJ, Suarez G, Reyes VE. H. pylori and host interactions that influence pathogenesis. World J Gastroenterol 2006; 12: 5599.
29. Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 1161.
30. Eriksson NK, Farkkila MA, Voutilainen ME, et al. The clinical value of taking routine biopsies from the incisura angularis during gastroscopy. Endoscopy 2005; 37: 532.
31. Everhart JE. Recent developments in the epidemiology of Helicobacter pylori. Gastroenterol Clin North Am 2000; 29: 559.
32. Ernst PB, Gold BD. The disease spectrum of Helicobacter pylori: the immunopathogenesis of gastroduodenal ulcer and gastric cancer. Annu Rev Microbiol 2000; 54: 615.
33. Perez-Perez GI, Dworkin BM, Chodos JE, et al. Campylobacter pylori antibodies in humans. Ann Intern Med 1988; 109: 11.
34. Tindberg Y, Bengtsson C, Granath F, et al. Helicobacter pylori infection in Swedish school children: lack of evidence of child-to-child transmission outside the family. Gastroenterology 2001; 121: 310.
35. Parsonnet J, Shmuely H, Haggerty T. Fecal and oral shedding of Helicobacter pylori from healthy infected adults. JAMA 1999; 282: 2240.
36. Clayton CL, Pallen MJ, Kleanthous H, et al. Nucleotide sequence of two genes from Helicobacter pylori encoding for urease subunits. Nucleic Acids Res 1990; 18: 362.
37. Dunn BE, Campbell GP, Perez-Perez GI, et al. Purification and characterization of urease from Helicobacter pylori. J Biol Chem 1990; 265: 9464.
38. Labigne A, Cussac V, Courcoux P. Shuttle cloning and nucleotide sequences of Helicobacter pylori genes responsible for urease activity. J Bacteriol 1991; 173: 1920.
39. Skouloubris S, Thiberge JM, Labigne A, et al. The Helicobacter pylori UreI protein is not involved in urease activity but is essential for bacterial survival in vivo. Infect Immun 1998; 66: 4517.
40. Eaton KA, Krakowka S. Effect of gastric pH on urease-dependent colonization of gnotobiotic piglets by Helicobacter pylori. Infect Immun 1994; 62: 3604.
41. Labigne A, de Reuse H. Determinants of Helicobacter pylori pathogenicity. Infect Agents Dis 1996; 5: 191.
42. Eaton KA, Suerbaum S, Josenhans C, et al. Colonization of gnotobiotic piglets by Helicobacter pylori deficient in two flagellin genes. Infect Immun 1996; 64: 2445.
43. Evans DG, Karjalainen TK, Evans DJ Jr, et al. Cloning, nucleotide sequence, and expression of a gene encoding an adhesin subunit protein of Helicobacter pylori. J Bacteriol 1993; 175: 674.
44. Lingwood CA, Huesca M, Kuksis A. The glycerolipid receptor for Helicobacter pylori (and exoenzyme S) is phosphatidylethanolamine. Infect Immun 1992; 60: 2470.
45. Lingwood CA, Wasfy G, Han H, et al. Receptor affinity purification of a lipid-binding adhesin from Helicobacter pylori. Infect Immun 1993; 61: 2474.
46. Gold BD, Huesca M, Sherman PM, et al. Helicobacter mustelae and Helicobacter pylori bind to common lipid receptors in vitro. Infect Immun 1993; 61: 2632.
47. Gerhard M, Lehn N, Neumayer N, et al. Clinical relevance of the Helicobacter pylori gene for blood-group antigen-binding adhesin. Proc Natl Acad Sci U S A 1999; 96: 12778.
48. Ilver D, Arnqvist A, Ogren J, et al. Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging. Science 1998; 279: 373.
49. Solnick JV, Hansen LM, Salama NR, et al. Modification of Helicobacter pylori outer membrane protein expression during experimental infection of rhesus macaques. Proc Natl Acad Sci U S A 2004; 101: 2106.
50. Mahdavi J, Sonden B, Hurtig M, et al. Helicobacter pylori SabA adhesin in persistent infection and chronic inflammation. Science 2002; 297: 573.
51. Cooke CL, Huff JL, Solnick JV. The role of genome diversity and immune evasion in persistent infection with Helicobacter pylori. FEMS Immunol Med Microbiol 2005; 45: 11.
52. Clyne M, Dillon P, Daly S, et al. Helicobacter pylori interacts with the human single-domain trefoil protein TFF1. Proc Natl Acad Sci U S A 2004; 101: 7409.
53. Kawakubo M, Ito Y, Okimura Y, et al. Natural antibiotic function of a human gastric mucin against Helicobacter pylori infection. Science 2004; 305: 1003.
54. Gobert AP, McGee DJ, Akhtar M, et al. Helicobacter pylori arginase inhibits nitric oxide production by eukaryotic cells: a strategy for bacterial survival. Proc Natl Acad Sci U S A 2001; 98: 13844.
55. Gewirtz AT, Navas TA, Lyons S, et al. Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J Immunol 2001; 167: 1882.
56. Donnelly MA, Steiner TS. Two nonadjacent regions in enteroaggregative Escherichia coli flagellin are required for activation of toll-like receptor 5. J Biol Chem 2002; 277: 40456.
57. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21: 335.
58. Perez-Perez GI, Shepherd VL, Morrow JD, et al. Activation of human THP-1 cells and rat bone marrow-derived macrophages by Helicobacter pylori lipopolysaccharide. Infect Immun 1995; 63: 1183.
59. Blaser MJ, Atherton JC. Helicobacter pylori persistence: biology and disease. J Clin Invest 2004; 113: 321.
60. Lee SK, Stack A, Katzowitsch E, et al. Helicobacter pylori flagellins have very low intrinsic activity to stimulate human gastric epithelial cells via TLR5. Microbes Infect 2003; 5: 1345.
61. Gewirtz AT, Yu Y, Krishna US, et al. Helicobacter pylori flagellin evades toll-like receptor 5-mediated innate immunity. J Infect Dis 2004; 189: 1914.
62. Andersen-Nissen E, Smith KD, Strobe KL, et al. Evasion of Toll-like receptor 5 by flagellated bacteria. Proc Natl Acad Sci U S A 2005; 102: 9247.
63. Gebert B, Fischer W, Weiss E, et al. Helicobacter pylori vacuolating cytotoxin inhibits T lymphocyte activation. Science 2003; 301: 1099.
64. Boncristiano M, Paccani SR, Barone S, et al. The Helicobacter pylori vacuolating toxin inhibits T cell activation by two independent mechanisms. J Exp Med 2003; 198: 1887.
65. Sundrud MS, Torres VJ, Unutmaz D, et al. Inhibition of primary human T cell proliferation by Helicobacter pylori vacuolating toxin (VacA) is independent of VacA effects on IL-2 secretion. Proc Natl Acad Sci U S A 2004; 101: 7727.
66. Amieva MR, Salama NR, Tompkins LS, et al. Helicobacter pylori enter and survive within multivesicular vacuoles of epithelial cells. Cell Microbiol 2002; 4: 677.
67. Zheng PY, Jones NL. Helicobacter pylori strains expressing the vacuolating cytotoxin interrupt phagosome maturation in macrophages by recruiting and retaining TACO (coronin 1) protein. Cell Microbiol 2003; 5: 25.
68. Oh JD, Karam SM, Gordon JI. Intracellular Helicobacter pylori in gastric epithelial progenitors. Proc Natl Acad Sci U S A 2005; 102: 5186.
69. Evans DG, Evans DJ, Jr., Moulds JJ, et al. N-acetylneuraminyllactose-binding fibrillar hemagglutinin of Campylobacter pylori: a putative colonization factor antigen. Infect Immun 1988; 56: 2896.
70. Crabtree JE, Shallcross TM, Wyatt JI, et al. Mucosal humoral immune response to Helicobacter pylori in patients with duodenitis. Dig Dis Sci 1991; 36: 1266.
71. Cover TL, Dooley CP, Blaser MJ. Characterization of and human serologic response to proteins in Helicobacter pylori broth culture supernatants with vacuolizing cytotoxin activity. Infect Immun 1990; 58: 603.
72. Crabtree JE, Taylor JD, Wyatt JI, et al. Mucosal IgA recognition of Helicobacter pylori 120 kDa protein, peptic ulceration, and gastric pathology. Lancet 1991; 338: 332.
73. Evans DJ Jr, Evans DG, Graham DY, et al. A sensitive and specific serologic test for detection of Campylobacter pylori infection. Gastroenterology 1989; 96: 1004.
74. Fox JG, Wang TC. Inflammation, atrophy, and gastric cancer. J Clin Invest 2007; 117: 60.
75. Bamford KB, Fan X, Crowe SE, et al. Lymphocytes in the human gastric mucosa during Helicobacter pylori have a T helper cell 1 phenotype. Gastroenterology 1998; 114: 482.
76. Haeberle HA, Kubin M, Bamford KB, et al. Differential stimulation of interleukin-12 (IL-12) and IL-10 by live and killed Helicobacter pylori in vitro and association of IL-12 production with gamma interferon-producing T cells in the human gastric mucosa. Infect Immun 1997; 65: 4229.
77. Hansson LE, Nyren O, Hsing AW, et al. The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med 1996; 335: 242.
78. McColl KE, el-Omar E, Gillen D, et al. The role of Helicobacter pylori in the pathophysiology of duodenal ulcer disease and gastric cancer. Semin Gastrointest Dis 1997; 8: 142.
79. Valle J, Kekki M, Sipponen P, et al. Long-term course and consequences of Helicobacter pylori gastritis. Results of a 32-year follow-up study. Scand J Gastroenterol 1996; 31: 546.
80. Sipponen P, Marshall BJ. Gastritis and gastric cancer. Western countries. Gastroenterol Clin North Am 2000; 29: 579.
81. You WC, Zhang L, Gail MH, et al. Precancerous lesions in two counties of China with contrasting gastric cancer risk. Int J Epidemiol 1998; 27: 945.
82. Tomb JF, White O, Kerlavage AR, et al. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 1997; 388: 539.
83. Alm RA, Ling LS, Moir DT, et al. Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature 1999; 397: 176.
84. Go MF, Kapur V, Graham DY, et al. Population genetic analysis of Helicobacter pylori by multilocus enzyme electrophoresis: extensive allelic diversity and recombinational population structure. J Bacteriol 1996; 178: 3934.
85. Salama N, Guillemin K, McDaniel TK, et al. A whole-genome microarray reveals genetic diversity among Helicobacter pylori strains. Proc Natl Acad Sci U S A 2000; 97: 14668.
86. Israel DA, Salama N, Krishna U, et al. Helicobacter pylori genetic diversity within the gastric niche of a single human host. Proc Natl Acad Sci U S A 2001; 98: 14625.
87. Censini S, Lange C, Xiang Z, et al. cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc Natl Acad Sci U S A 1996; 93: 14648.
88. Akopyants NS, Clifton SW, Kersulyte D, et al. Analyses of the cag pathogenicity island of Helicobacter pylori. Mol Microbiol 1998; 28: 37.
89. Peek RM Jr, Miller GG, Tham KT, et al. Heightened inflammatory response and cytokine expression in vivo to cagA+ Helicobacter pylori strains. Lab Invest 1995; 73: 760.
90. Peek RM Jr, Miller GG, Tham KT, et al. Detection of Helicobacter pylori gene expression in human gastric mucosa. J Clin Microbiol 1995; 33: 28.
91. Kuipers EJ, Perez-Perez GI, Meuwissen SG, et al. Helicobacter pylori and atrophic gastritis: importance of the cagA status. J Natl Cancer Inst 1995; 87: 1777.
92. Crabtree JE, Wyatt JI, Sobala GM, et al. Systemic and mucosal humoral responses to Helicobacter pylori in gastric cancer. Gut 1993; 34: 1339.
93. Blaser MJ, Perez-Perez GI, Kleanthous H, et al. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res 1995; 55: 2111.
94. Parsonnet J, Friedman GD, Orentreich N, et al. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut 1997; 40: 297.
95. Rudi J, Kolb C, Maiwald M, et al. Serum antibodies against Helicobacter pylori proteins VacA and CagA are associated with increased risk for gastric adenocarcinoma. Dig Dis Sci 1997; 42: 1652.
96. Queiroz DM, Mendes EN, Rocha GA, et al. cagA-positive Helicobacter pylori and risk for developing gastric carcinoma in Brazil. Int J Cancer 1998; 78: 135.
97. Torres J, Perez-Perez GI, Leal-Herrera Y, et al. Infection with CagA+ Helicobacter pylori strains as a possible predictor of risk in the development of gastric adenocarcinoma in Mexico. Int J Cancer 1998; 78: 298.
98. Vorobjova T, Nilsson I, Kull K, et al. CagA protein seropositivity in a random sample of adult population and gastric cancer patients in Estonia. Eur J Gastroenterol Hepatol 1998; 10: 41.
99. Shimoyama T, Fukuda S, Tanaka M, et al. CagA seropositivity associated with development of gastric cancer in a Japanese population. J Clin Pathol 1998; 51: 225.
100. Segal ED, Cha J, Lo J, et al. Altered states: involvement of phosphorylated CagA in the induction of host cellular growth changes by Helicobacter pylori. Proc Natl Acad Sci U S A 1999; 96: 14559.
101. Odenbreit S, Puls J, Sedlmaier B, et al. Translocation of Helicobacter pylori CagA into gastric epithelial cells by type IV secretion. Science 2000; 287: 1497.
102. Stein M, Rappuoli R, Covacci A. Tyrosine phosphorylation of the Helicobacter pylori CagA antigen after cag-driven host cell translocation. Proc Natl Acad Sci U S A 2000; 97: 1263.
103. Asahi M, Azuma T, Ito S, et al. Helicobacter pylori CagA protein can be tyrosine phosphorylated in gastric epithelial cells. J Exp Med 2000; 191: 593.
104. Hatakeyama M. Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat Rev Cancer 2004; 4: 688.
105. Backert S, Ziska E, Brinkmann V, et al. Translocation of the Helicobacter pylori CagA protein in gastric epithelial cells by a type IV secretion apparatus. Cell Microbiol 2000; 2: 155.
106. Selbach M, Moese S, Hauck CR, et al. Src is the kinase of the Helicobacter pylori CagA protein in vitro and in vivo. J Biol Chem 2002; 277: 6775.
107. Stein M, Bagnoli F, Halenbeck R, et al. c-Src/Lyn kinases activate Helicobacter pylori CagA through tyrosine phosphorylation of the EPIYA motifs. Mol Microbiol 2002; 43: 971.
108. Higashi H, Tsutsumi R, Muto S, et al. SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science 2002; 295: 683.
109. Higashi H, Tsutsumi R, Fujita A, et al. Biological activity of the Helicobacter pylori virulence factor CagA is determined by variation in the tyrosine phosphorylation sites. Proc Natl Acad Sci U S A 2002; 99: 14428.
110. Tsutsumi R, Higashi H, Higuchi M, et al. Attenuation of Helicobacter pylori CagA-SHP-2 signaling by interaction between CagA and C-terminal Src kinase. J Biol Chem 2003; 278: 3640.
111. Glocker E, Lange C, Covacci A, et al. Proteins encoded by the cag pathogenicity island of Helicobacter pylori are required for NFkappaB activation. Infect Immun 1998; 66: 2346.
112. Keates S, Keates AC, Warny M, et al. Differential activation of mitogen-activated protein kinases in AGS gastric epithelial cells by cag+ and cag-Helicobacter pylori. J Immunol 1999; 163: 5552.
113. Naumann M, Wessler S, Bartsch C, et al. Activation of activator protein 1 and stress response kinases in epithelial cells colonized by Helicobacter pylori encoding the cag pathogenicity island. J Biol Chem 1999; 274: 31655.
114. Crabtree JE, Kersulyte D, Li SD, et al. Modulation of Helicobacter pylori induced interleukin-8 synthesis in gastric epithelial cells mediated by cag PAI encoded VirD4 homologue. J Clin Pathol 1999; 52: 653.
115. Meyer-Ter-Vehn T, Covacci A, Kist M, et al. Helicobacter pylori activates mitogen-activated protein kinase cascades and induces expression of the proto-oncogenes c-fos and c-jun. J Biol Chem 2000; 275: 16064.
116. Fischer W, Puls J, Buhrdorf R, et al. Systematic mutagenesis of the Helicobacter pylori cag pathogenicity island: essential genes for CagA translocation in host cells and induction of interleukin-8. Mol Microbiol 2001; 42: 1337.
117. Amieva MR, Vogelmann R, Covacci A, et al. Disruption of the epithelial apical-junctional complex by Helicobacter pylori CagA. Science 2003; 300: 1430.
118. Bagnoli F, Buti L, Tompkins L, et al. Helicobacter pylori CagA induces a transition from polarized to invasive phenotypes in MDCK cells. Proc Natl Acad Sci U S A 2005; 102: 16339.
119. Murata-Kamiya N, Kurashima Y, Teishikata Y, et al. Helicobacter pylori CagA interacts with E-cadherin and deregulates the betacatenin signal that promotes intestinal transdifferentiation in gastric epithelial cells. Oncogene 2007; 26: 4617.
120. Cover TL, Blaser MJ. Purification and characterization of the vacuolating toxin from Helicobacter pylori. J Biol Chem 1992; 267: 10570.
121. Cover TL, Tummuru MK, Cao P, et al. Divergence of genetic sequences for the vacuolating cytotoxin among Helicobacter pylori strains. J Biol Chem 1994; 269: 10566.
122. Telford JL, Ghiara P, Dell'Orco M, et al. Gene structure of the Helicobacter pylori cytotoxin and evidence of its key role in gastric disease. J Exp Med 1994; 179: 1653.
123. Schmitt W, Haas R. Genetic analysis of the Helicobacter pylori vacuolating cytotoxin: structural similarities with the IgA protease type of exported protein. Mol Microbiol 1994; 12: 307.
124. Phadnis SH, Ilver D, Janzon L, et al. Pathological significance and molecular characterization of the vacuolating toxin gene of Helicobacter pylori. Infect Immun 1994; 62: 1557.
125. Atherton JC, Cao P, Peek RM Jr, et al. Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori. Association of specific vacA types with cytotoxin production and peptic ulceration. J Biol Chem 1995; 270: 17771.
126. van Doorn LJ, Figueiredo C, Sanna R, et al. Expanding allelic diversity of Helicobacter pylori vacA. J Clin Microbiol 1998; 36: 2597.
127. van Doorn LJ, Figueiredo C, Megraud F, et al. Geographic distribution of vacA allelic types of Helicobacter pylori. Gastroenterology 1999; 116: 823.
128. Miehlke S, Kirsch C, Agha-Amiri K, et al. The Helicobacter pylori vacA s1, m1 genotype and cagA is associated with gastric carcinoma in Germany. Int J Cancer 2000; 87: 322.
129. Miehlke S, Yu J, Schuppler M, et al. Helicobacter pylori vacA, iceA, and cagA status and pattern of gastritis in patients with malignant and benign gastroduodenal disease. Am J Gastroenterol 2001; 96: 1008.
130. Louw JA, Kidd MS, Kummer AF, et al. The relationship between Helicobacter pylori infection, the virulence genotypes of the infecting strain and gastric cancer in the African setting. Helicobacter 2001; 6: 268.
131. Atherton JC, Peek RM Jr, Tham KT, et al. Clinical and pathological importance of heterogeneity in vacA, the vacuolating cytotoxin gene of Helicobacter pylori. Gastroenterology 1997; 112: 92.
132. Ghiara P, Marchetti M, Blaser MJ, et al. Role of the Helicobacter pylori virulence factors vacuolating cytotoxin, CagA, and urease in a mouse model of disease. Infect Immun 1995; 63: 4154.
133. Yamaoka Y, Kwon DH, Graham DY. A M(r) 34 000 proinflammatory outer membrane protein (oipA) of Helicobacter pylori. Proc Natl Acad Sci U S A 2000; 97: 7533.
134. Yamaoka Y, Kikuchi S, el-Zimaity HM, et al. Importance of Helicobacter pylori oipA in clinical presentation, gastric inflammation, and mucosal interleukin 8 production. Gastroenterology 2002; 123: 414.
135. Noach LA, Bosma NB, Jansen J, et al. Mucosal tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8 production in patients with Helicobacter pylori infection. Scand J Gastroenterol 1994; 29: 425.
136. Beales IL, Calam J. Interleukin 1 beta and tumour necrosis factor alpha inhibit acid secretion in cultured rabbit parietal cells by multiple pathways. Gut 1998; 42: 227.
137. El-Omar EM. The importance of interleukin 1beta in Helicobacter pylori associated disease. Gut 2001; 48: 743.
138. El-Omar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404: 398.
139. Machado JC, Pharoah P, Sousa S, et al. Interleukin 1B and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma. Gastroenterology 2001; 121: 823.
140. Furuta T, El-Omar EM, Xiao F, et al. Interleukin 1beta polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan. Gastroenterology 2002; 123: 92.
141. Crabtree JE, Shallcross TM, Heatley RV, et al. Mucosal tumour necrosis factor alpha and interleukin-6 in patients with Helicobacter pylori associated gastritis. Gut 1991; 32: 1473.
142. El-Omar EM, Rabkin CS, Gammon MD, et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 2003; 124: 1193.
143. Figueiredo C, Machado JC, Pharoah P, et al. Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst 2002; 94: 1680.
144. Peek RM Jr. The biological impact of Helicobacter pylori colonization. Semin Gastrointest Dis 2001; 12: 151.
145. Peek RM. Helicobacter pylori and gastroesophageal reflux disease. Curr Treat Options Gastroenterol 2004; 7: 59.
146. Basset C, Holton J, Gatta L, et al. Helicobacter pylori infection: anything new should we know? Aliment Pharmacol Ther 2004; 20 (Suppl. 2): 31.
147. Makristathis A, Hirschl AM, Lehours P, et al. Diagnosis of Helicobacter pylori infection. Helicobacter 2004; 9 (Suppl. 1): 7.
148. el-Zimaity HM, al-Assi MT, Genta RM, et al. Confirmation of successful therapy of Helicobacter pylori infection: number and site of biopsies or a rapid urease test. Am J Gastroenterol 1995; 90: 1962.
149. el-Zimaity HM, Graham DY. Evaluation of gastric mucosal biopsy site and number for identification of Helicobacter pylori or intestinal metaplasia: role of the Sydney System. Hum Pathol 1999; 30: 72.
150. Xia HX, Keane CT, O'Morain CA. Pre-formed urease activity of Helicobacter pylori as determined by a viable cell count technique -clinical implications. J Med Microbiol 1994; 40: 435.
151. Basso D, Navaglia F, Cassaro M, et al. Gastric juice polymerase chain reaction: an alternative to histology in the diagnosis of Helicobacter pylori infection. Helicobacter 1996; 1: 159.
152. Jiang C, Li C, Ha T, et al. Identification of H. pylori in saliva by a nested PCR assay derived from a newly cloned DNA probe. Dig Dis Sci 1998; 43: 1211.
153. Li C, Ha T, Ferguson DA, et al. A newly developed PCR assay of H. pylori in gastric biopsy, saliva, and feces. Evidence of high prevalence of H. pylori in saliva supports oral transmission. Dig Dis Sci 1996; 41: 2142.
154. Banatvala N, Lopez CR, Owen R, et al. Helicobacter pylori in dental plaque. Lancet 1993; 341: 380.
155. Kelly SM, Pitcher MC, Farmery SM, et al. Isolation of Helicobacter pylori from feces of patients with dyspepsia in the United Kingdom. Gastroenterology 1994; 107: 1671.
156. Leodolter A, Vaira D, Bazzoli F, et al. European multicentre validation trial of two new non-invasive tests for the detection of Helicobacter pylori antibodies: urine-based ELISA and rapid urine test. Aliment Pharmacol Ther 2003; 18: 927.
157. Okuda M, Nakazawa T, Booka M, et al. Evaluation of a urine antibody test for Helicobacter pylori in Japanese children. J Pediatr 2004; 144: 196.
158. Shimizu T, Yarita Y, Haruna H, et al. Urine-based enzyme-linked immunosorbent assay for the detection of Helicobacter pylori antibodies in children. J Paediatr Child Health 2003; 39: 606.
159. Kosunen TU, Seppala K, Sarna S, et al. Diagnostic value of decreasing IgG, IgA, and IgM antibody titres after eradication of Helicobacter pylori. Lancet 1992; 339: 893.
160. Cutler AF, Prasad VM, Santogade P. Four-year trends in Helicobacter pylori IgG serology following successful eradication. Am J Med 1998; 105: 18.
161. Atherton JC. H. pylori virulence factors. Br Med Bull 1998; 54: 105.
162. Vaira D, Malfertheiner P, Megraud F, et al. Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay. HpSA European study group. Lancet 1999; 354: 30.
163. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection -The Maastricht III Consensus Report. Gut 2007.
164. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection -the Maastricht 22000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167.
165. Miehlke S, Bayerdorffer E, Graham DY. Treatment of Helicobacter pylori infection. Semin Gastrointest Dis 2001; 12: 167.
166. McLoughlin R, Racz I, Buckley M, et al. Therapy of Helicobacter pylori. Helicobacter 2004; 9 (Suppl. 1): 42.
167. Ulmer HJ, Beckerling A, Gatz G. Recent use of proton pump inhibitor-based triple therapies for the eradication of H. pylori: a broad data review. Helicobacter 2003; 8: 95.
168. Vaira D, Holton J, Ricci C, et al. Review article: Helicobacter pylori infection from pathogenesis to treatment -a critical reappraisal. Aliment Pharmacol Ther 2002; 16: 105.
169. Zullo A, Vaira D, Vakil N, et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 2003; 17: 719.
170. Basset C, Holton J, Ricci C, et al. Diagnosis and treatment of Helicobacter: a 2002 updated review. Aliment Pharmacol Ther 2003; 17: 89.
171. Williams C. Occurrence and significance of gastric colonization during acid-inhibitory therapy. Best Pract Res Cl Ga 2001; 15: 511.
172. Kavalar R, Skok P, Kramberger KG. Phlegmonous gastritis in a patient with rheumatoid arthritis. Wiener Klinische Wochenschrift 2005; 117: 364.
173. Lee BS, Kim SM, Seong JK, et al. Phlegmonous gastritis after endoscopic mucosal resection. Endoscopy 2005; 37: 490.
174. Lifton LJ, Shlossberg D. Phlegmonous gastritis after endoscopic polypectomy. Ann Int Med 1982; 97: 373.
175. Ocepek A, Skok P, Virag M, et al. Emphysematous gastritis -case report and review of the literature. Zeitschrift fur Gastroenterologie 2004; 42: 735.
176. Massironi S, Carmagnola S, Penagini R, et al. Gastric involvement in a patient with secondary syphilis. Digest Liver Dis 2005; 37: 368.
177. Guerrero AF, Straight TM, Eastone J, et al. Gastric syphilis in an HIV-infected patient. AIDS Patient Care St 2005; 19: 281.
178. Amarapurkar DN, Patel ND, Amarapurkar AD. Primary gastric tuberculosis -report of 5 cases. BMC Gastroenterology 2003; 3: 6.
179. Maiorana A, Baccarini P, Foroni M, et al. Human cytomegalovirus infection of the gastrointestinal tract in apparently immunocompetent patients. Hum Pathol 2003; 34: 1331.
180. Sarkio S, Halme L, Arola J, et al. Gastroduodenal cytomegalovirus infection is common in kidney transplantation patients. Scand J Gastroenterol 2005; 40: 508.
181. Chang HR. Posttransplant cytomegalovirus disease presenting with pyloric obstruction. Transplantation 2005; 79: 1462.
182. Zwolinska-Wcislo M, Budak A, Bogdal J, et al. Fungal colonization of gastric mucosa and its clinical relevance. Med Sci Monitor 2001; 7: 982.
183. Sanguino J, Rodrigues B, Baptista A, et al. Focal lesion of African histoplasmosis present as a malignant gastric ulcer. Hepatogastroenterology 1996; 43: 771.
184. Washington K, Gottfried MR, Wilson ML. Gastrointestinal cryptococcosis. Modern Pathol 1991; 4: 707.
185. Stamm B. Mucormycosis of the stomach in a patient with multiple trauma. Histopathology 2005; 47: 222.
186. Pampiglione S, Rivasi F, Criscuolo M, et al. Human anisakiasis in Italy: a report of eleven new cases. Pathol Res Pract 2002; 198: 429.
187. Moon A, Spivak W, Brandt LJ. Cryptosporidium-induced gastric obstruction in a child with congenital HIV infection: case report and review of the literature. J Pediatr Gastr Nutr 1999; 28: 108.
188. Doglioni C, De Boni M, Cielo R, et al. Gastric giardiasis. J Clin Pathol 1992; 45: 964.
189. Thompson BF, Fry LC, Wells CD, et al. The spectrum of GI strongyloidiasis: an endoscopic-pathologic study. Gastrointest Endosc 2004; 59: 906.
190. Rothenberg ME. Eosinophilic gastrointestinal disorders (EGID). J Allergy Clin Immun 2004; 113: 11.
191. Talley NJ, Shorter RG, Phillips SF, et al. Eosinophilic gastroenteritis: a clinicopathologic study of patients with disease of the mucosa, muscle layer, and subserosal tissues. Gut 1990; 31: 54.
192. Barbie DA, Mangi AA, Lauwers GY. Eosinophilic gastroenteritis associated with systemic lupus erythematosus. J Clin Gastroenterol 2004; 38: 883.
193. Gomez B, Tabar AI, Tunon T, et al. Eosinophilic gastroenteritis and Anisakis. Allergy 1998; 53: 1148.
194. Maeng L, Lee A, Choi K, et al. Granulomatous gastritis: a clinicopathologic analysis of 18 biopsy cases. Am J Surg Pathol 2004; 28: 941.
195. Shapiro JL, Goldblum JR, Petras RE. A clinicopathologic study of 42 patients with granulomatous gastritis: is there really an "idiopathic" granulomatous gastritis? Am J Surg Pathol 1996; 20: 462.
196. Shigematsu H, Kurita A, Omura Y, et al. Gastric cancer with sarcoid reactions in the regional lymph nodes, the stomach wall, and the splenic parenchyma: report of a case. Surgery Today 1999; 29: 549.
197. Leach IH, Maclennan KA. Gastric lymphoma associated with mucosal and nodal granulomas: a new differential diagnosis in granulomatous gastritis. Histopathology 1990; 17: 87.
198. Asakawa H, Tsuji M, Tokumine Y, et al. Gastric T-cell lymphoma presenting with epithelioid granulomas mimicking tuberculosis in regional lymph nodes. J Gastroenterol 2001; 36: 190.
199. Ectors NL, Dixon MF, Geboes KJ, et al. Granulomatous gastritis: a morphological and diagnostic approach. Histopathology 1993; 23: 55.
200. Oberhuber G, Puspok A, Oesterreicher C, et al. Focally enhanced gastritis: a frequent type of gastritis in patients with Crohn's disease. Gastroenterology 1997; 112: 698.
201. Parente F, Cucino C, Bollani S, et al. Focal gastric inflammatory infiltrates in inflammatory bowel diseases: prevalence, immunohistochemical characteristics, and diagnostic role. Am J Gastroenterol 2000; 95: 705.
202. Sharif F, McDermott M, Dillon M, et al. Focally enhanced gastritis in children with Crohn's disease and ulcerative colitis. Am J Gastroenterol 2002; 97: 1415.
203. Xin W, Greenson JK. The clinical significance of focally enhanced gastritis. Am J Surg Pathol 2004; 28: 1347.
204. Grubel P, Choi Y, Schneider D, et al. Severe isolated Crohn's-like disease of the gastroduodenal tract. Digest Dis Sci 2003; 48: 1360.
205. Yamamoto T, Allan RN, Keighley MR. An audit of gastroduodenal Crohn disease: clinicopathologic features and management. Scand J Gastroenterol 1999; 34: 1019.
206. Fireman Z, Sternberg A, Yarchovsky Y, et al. Multiple antral ulcers in gastric sarcoid. J Clin Gastroenterol 1997; 24: 97.
207. Capella C, Fiocca R, Cornaggia M, et al. Autoimmune gastritis. In: Graham D, Genta RM, Dixon MF (eds). Gastritis. Philadephia: Lippincott Williams & Wilkins, 1999: 79.
208. D'Elios MM, Appelmelk BJ, Amedei A, et al. Gastric autoimmunity: the role of Helicobacter pylori and molecular mimicry. Trends Mol Med 2004; 10: 316.
209. Torbenson M, Abraham SC, Boitnott J, et al. Autoimmune gastritis: distinct histological and immunohistochemical findings before complete loss of oxyntic glands. Modern Pathol 2002; 15: 102.
210. Wolber RA, Owen D, DelBuono L, et al. Lymphocytic gastritis in patients with celiac sprue or spruelike intestinal disease. Gastroenterology 1990; 98: 310.
211. Wu TT, Hamilton SR. Lymphocytic gastritis: association with etiology and topology. Am J Surg Pathol 1999; 23: 153.
212. Perardi S, Todros L, Musso A, et al. Lymphocytic gastritis and protein-losing gastropathy. Digest Liver Dis 2000; 32: 422.
213. Lagorce-Pages C, Fabiani B, Bouvier R, et al. Collagenous gastritis: a report of six cases. Am J Surg Pathol 2001; 25: 1174.
214. Stancu M, De Petris G, Palumbo TP, et al. Collagenous gastritis associated with lymphocytic gastritis and celiac disease. Arch Pathol Lab Med 2001; 125: 1579.
215. Quinn CM, Bjarnason I, Price AB. Gastritis in patients on non-steroidal anti-inflammatory drugs. Histopathology 1993; 23: 341.
216. Fiorucci S, Antonelli E, Morelli A. Mechanism of non-steroidal anti-inflammatory drug-gastropathy. Digest Liver Dis 2001; 33(Suppl. 2): S35.
217. Kodali VP, Gordon SC. Gastrointestinal hemorrhage secondary to crack cocaine. Gastrointest Endosc 1995; 41: 604.
218. Curling TB. On acute ulceration of the duodenum in cases of burn. Med Chir Trans, Second Series 1842; 25: 260.
219. Yang YX, Lewis JD. Prevention and treatment of stress ulcers in critically ill patients. Semin Gastrointest Dis 2003; 14: 11.
220. van der Voort PH, van der Hulst RW, Zandstra DF, et al. Prevalence of Helicobacter pylori infection in stress-induced gastric mucosal injury. Intens Care Med 2001; 27: 68.
221. Raja K, Kochlar R, Sethy PK, et al. An endoscopic study of upper-GI mucosal changes in patients with congestive heart failure. Gastrointest Endosc 2004; 60: 887.
222. Merli M, Nicolini G, Angeloni S, et al. The natural history of portal hypertensive gastropathy in patients with liver cirrhosis and mild portal hypertension. Am J Gastroenterol 2004; 99: 1959.
223. Thuluvath PJ, Yoo HY. Portal hypertensive gastropathy. Am J Gastroenterol 2002; 97: 2973.
224. Stewart CA, Sanyal AJ. Grading portal gastropathy: validation of a gastropathy scoring system. Am J Gastroenterol 2003; 98: 1758.
225. McCormack TT, Sims J, Eyre-Brook I, et al. Gastric lesions in portal hypertension: inflammatory gastritis or congestive gastropathy? Gut 1985; 26: 1226.
226. Chouraqui JP, Roy CC, Brochu P, et al. Menetrier's disease in children: report of a patient and review of sixteen other cases. Gastroenterology 1981; 80: 1042.
227. Morinville V, Bernard C, Forget S. Foveolar hyperplasia secondary to cow's milk protein hypersensitivity presenting with clinical features of pyloric stenosis. J Pediatr Surg 2001; 39: E29.
228. Xiao SY, Hart J. Marked gastric foveolar hyperplasia associated with active cytomegalovirus infection. Am J Gastroenterol 2001; 96: 223.
229. Burdick JS, Chung E, Tanner G, et al. Treatment of Menetrier's disease with a monoclonal antibody against the epidermal growth factor receptor. N Engl J Med 2000; 343: 1697.
230. Goldblum JR, Richter JE, Vaezi M, et al. Helicobacter pylori infection, not gastroesophageal reflux, is the major cause of inflammation and intestinal metaplasia of gastric cardiac mucosa. Am J Gastroenterol 2002; 97: 302.
231. Genta RM, Hiihorman RM, Graham DY. The gastric cardia in Helicobacter pylori infection. Hum Pathol 1994; 25: 915.
232. Voutilainen M, Farkkila M, Juhola M, et al. Complete and incomplete intestinal metaplasia at the oesophagogastric junction: prevalences and associations with endoscopic erosive oesophagitis and gastritis. Gut 1999; 45: 644.
233. Wolf C, Seldenrijk CA, Timmer R, et al. Does carditis have two different etiologies? Digest Dis Sci 2001; 46: 2424.
234. Goldblum JR, Vicari JJ, Falk GW, et al. Inflammation and intestinal metaplasia of the gastric cardia: the role of gastroesophageal reflux and H. pylori infection. Gastroenterology 1998; 114: 633.
235. Ormsby AH, Vaezi MF, Richter JE, et al. Cytokeratin immunoreactivity patterns in the diagnosis of short-segment Barrett's esophagus. Gastroenterology 2000; 119: 683.
236. el-Zimaity HM, Graham DY. Cytokeratin subsets for distinguishing Barrett's esophagus from intestinal metaplasia in the cardia using endoscopic biopsy specimens. Am J Gastroenterol 2001; 96: 1378.
237. Schilling D, Speithoff A, Rosenbaum A, et al. Does cytokeratin 7/20 immunoreactivity help to distinguish Barrett's esophagus from gastric intestinal metaplasia? Results of a prospective study of 75 patients. Pathol Res Pract 2005; 200: 801.